Wave life sciences highlights growing pipeline at research day, including inhbe sirna program for obesity and new rna editing programs

Wve-007 (inhbe galnac-sirna for obesity) is on track to initiate a clinical trial in 1q 2025; new preclinical data for wve-007 demonstrate opportunities for monotherapy, for synergistic use with glp-1s, and for maintenance to avoid rebound weight gain following cessation of glp-1s
WVE Ratings Summary
WVE Quant Ranking